Cargando…

Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells

Detalles Bibliográficos
Autores principales:	Yin, Linglong, Liu, Youhong, Peng, Yuchong, Peng, Yongbo, Yu, Xiaohui, Gao, Yingxue, Yuan, Bowen, Zhu, Qianling, Cao, Tuoyu, He, Leye, Gong, Zhicheng, Sun, Lunquan, Fan, Xuegong, Li, Xiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862322/ https://www.ncbi.nlm.nih.gov/pubmed/35193658 http://dx.doi.org/10.1186/s13046-022-02290-9

Ejemplares similares

PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
por: Yin, Linglong, et al.
Publicado: (2018)

FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness
por: Yuan, Bowen, et al.
Publicado: (2018)

Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition
por: Yu, Xiaohui, et al.
Publicado: (2018)

AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer
por: Fu, Yongming, et al.
Publicado: (2023)

Phosphorus containing analogues of SAHA as inhibitors of HDACs
por: Pun, Michael D., et al.
Publicado: (2022)

Effect of the PARP inhibitor veliparib on germ cell tumor cell lines
por: Schmidtova, Silvia, et al.
Publicado: (2022)

USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis
por: Peng, Yuchong, et al.
Publicado: (2019)

PLK1 maintains DNA methylation and cell viability by regulating phosphorylation-dependent UHRF1 protein stability
por: Peng, Yuchong, et al.
Publicado: (2023)

Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma
por: Wang, Jing, et al.
Publicado: (2022)

The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells
por: Hou, Youxiang, et al.
Publicado: (2017)

Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells
por: Moertl, Simone, et al.
Publicado: (2019)

In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC)
por: Tambunan, Usman SF, et al.
Publicado: (2011)

Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells
por: Natarajan, Umamaheswari, et al.
Publicado: (2018)

Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report
por: VanderWeele, David J., et al.
Publicado: (2015)

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
por: Tuli, R., et al.
Publicado: (2019)

FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription
por: Liu, Youhong, et al.
Publicado: (2017)

The HDAC Inhibitor, SAHA, Prevents Colonic Inflammation by Suppressing Pro-inflammatory Cytokines and Chemokines in DSS-induced Colitis
por: Ali, Mohmand Noor, et al.
Publicado: (2018)

The HDAC Inhibitor, SAHA, Combined with Cisplatin Synergistically Induces Apoptosis in Alpha-fetoprotein-producing Hepatoid Adenocarcinoma Cells
por: Kyaw, Myat Tin Htwe, et al.
Publicado: (2019)

HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics
por: Araujo-Silva, Carlla Assis, et al.
Publicado: (2020)

Synthesis of Veliparib Prodrugs and Determination of Drug-Release-Dependent PARP-1 Inhibition
por: Borgini, Matteo, et al.
Publicado: (2023)

A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients
por: Stodtmann, Sven, et al.
Publicado: (2021)

A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
por: Ramos, Louise, et al.
Publicado: (2023)

The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia
por: Di Costanzo, Antonella, et al.
Publicado: (2018)

High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects
por: Li, Xia, et al.
Publicado: (2018)

Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α
por: Citro, Simona, et al.
Publicado: (2019)

Cardiomyogenic Differentiation Potential of Human Dilated Myocardium-Derived Mesenchymal Stem/Stromal Cells: The Impact of HDAC Inhibitor SAHA and Biomimetic Matrices
por: Miksiunas, Rokas, et al.
Publicado: (2021)

Methylated-UHRF1 and PARP1 interaction is critical for homologous recombination
por: Hahm, Ja Young, et al.
Publicado: (2020)

Histone Deacetylases (HDAC) Inhibitor—Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor
por: Drzewiecka, Małgorzata, et al.
Publicado: (2023)

A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells †
por: Ahmed, Ahmed Abdullah, et al.
Publicado: (2020)

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
por: Min, Ahrum, et al.
Publicado: (2015)

Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC
por: Cao, Jiangying, et al.
Publicado: (2020)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS
por: Vollmer, Johanna, et al.
Publicado: (2020)

Molecular dynamics simulation of complex Histones Deacetylase (HDAC) Class II Homo Sapiens with suberoylanilide hydroxamic acid (SAHA) and its derivatives as inhibitors of cervical cancer
por: Tambunan, Usman Sumo Friend, et al.
Publicado: (2013)

In Vitro and In Vivo Efficacy of DNA Damage Repair Inhibitor Veliparib in Combination with Artesunate against Echinococcus granulosus
por: Li, Y. F., et al.
Publicado: (2020)

Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway
por: Shi, Xuan-Yan, et al.
Publicado: (2017)

Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression
por: Wang, Qun, et al.
Publicado: (2016)

Dissection of Anti-tumor Activity of Histone Deacetylase Inhibitor SAHA in Nasopharyngeal Carcinoma Cells via Quantitative Phosphoproteomics
por: Huang, Huichao, et al.
Publicado: (2020)

Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells
por: Grabarska, Aneta, et al.
Publicado: (2017)

Histone Deacetylase Inhibitor (SAHA) Reduces Mortality in an Endotoxemia Mouse Model by Suppressing Glycolysis
por: Wu, Yunchen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sk2rd9eedkjoi1jng97t6i9a5l